Zomedica (NYSEAMERICAN:ZOM) may not be a profitable company yet but it has emerged as one of the penny stocks that is getting considerable attention from investors.
Moreover, it is important to note that the company is involved in the fast-growing animal healthcare space. Additionally, the company recently launched a product as well in the form of its diagnostic platform for cats and dogs named Truforma. Hence, the stock is not entirely speculative in nature although it become a part of the ‘meme stock’ trend.
However, if Zomedica has to grow and gain the confidence of the markets then it is necessary for the company to grow its revenues. Once it manages to grow its revenues to a certain level then Zomedica’s valuations could actually be justified. To that end, Zomedica recently changed its sales strategy and moved to a direct sales model. However, the move was not welcomed by investors and the stock actually declined.
Biotech, Tech, and Crypto reporter
Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.